Cabozantinib/Atezolizumab for Metastatic Colorectal Cancer: Thomas Abrams, MD

In this interview, Dr. Thomas Abrams of Harvard Medical School discusses the role that cabozantinib/atezolizumab may play for patients with metastatic colorectal cancer, particularly those with RAS wild-type disease, in the coming years.